Abstract
Lapatinib is an oral, small-molecule dual inhibitor of human EGF receptor 1 (EGFR/erbB1) and 2 (HER2/erbB2). Lapatinib has recently been approved, in combination with capecitabine, for the treatment of HER2-positive metastatic breast cancer patients failing trastuzumab therapy. Data from clinical trials are consistently showing the key role of this agent in the management of HER2-positive disease. Moreover, interesting data are suggesting a key role of lapatinib in enhancing endocrine responsiveness and/or restoring endocrine sensitivity in hormone receptorpositive disease. The present article will summarize the main data leading to the clinical development of the combination of lapatinib and the aromatase inhibitor letrozole.
| Original language | English |
|---|---|
| Pages (from-to) | 1549-1557 |
| Number of pages | 9 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 9 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 2009 |
Keywords
- Advanced breast cancer
- HER2 positive
- Hormone receptor positive
- Lapatinib
- Letrozole
- Trastuzumab
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology